Australia's Hexima hits record high on China patent for fungal infection treatment

Hexima

24/08/2021 05:32

** Shares of Hexima Ltd  HXL.AX  jump as much as 34.62% to
A$0.35 - record high since debut on ASX in December last year
    ** Biotech firm says https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02410836-3A573607?access_token=83ff96335c2d45a094df02a206a39ff4
 granted China patent for its topical treatment of toenail
fungal infection
    ** Says patent protection until at least 2035 in China
    ** Earlier on July 14, HXL was granted European patent https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02395122-3A570715?access_token=83ff96335c2d45a094df02a206a39ff4
    ** Stock posts its biggest intra-day pct gain ever, before
paring gains to trade at A$0.295 as of 0402 GMT
    ** Almost 800,000 shares change hands, about 9x their 30-day
avg
    ** Stock's busiest trading day since its listing 
    ** Stock up 40.54% YTD, as of last close on Aug. 20
    


 (Reporting by Dhriti Garg in Bengaluru)
 ((Dhriti.Garg@thomsonreuters.com))